Literature DB >> 951577

Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.

I M Nilsson, U Hedner.   

Abstract

9 patients with severe haemophilia A and inhibitors (inhibitor levels between 0.1 to 5.8 U/ml) and 3 patients with severe haemophilia B and inhibitors (inhibitor levels between 0.1 to 11 U/ml) were treated on a total of 16 and 13 occasions, respectively, with a large dose of antigen (factor VIII or factor IX) and cyclophosphamide (10-15 mg/kg b.w. i.v. initially and then 2-3 mg/kg b.w. orally for 7-10 days) in connection with severe bleeding and surgery. All the patients had proved not to respond to treatment with factor VIII or factor IX concentrate alone, and all except one had shown strong secondary antibody increases. In 6 of the patients with haemophilia A the treatment (11 occasions) had a satisfactory haemostatic effect and even permitted neurosurgery without bleeding complications. The inhibitor level remained at zero for 5-10 days, after which it gradually began to return towards its original level. In these cases it was possible to give factor VIII in amounts which neutralised the inhibitor and afterwards raised the factor VIII initially to at least 50%. In the 3 patients with haemophilia B treatment (13 occasions) was successful except on one occasion, and surgery was performed without abnormal bleeding. The factor IX level was initially raised to at least 50% except in the one failure. The inhibitor level remained at zero for 12 days to 3 months, after which it gradually rose towards its original level. One patient was treated on 8 occasions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 951577     DOI: 10.1111/j.1600-0609.1976.tb00330.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  8 in total

1.  Surgery of hemophiliacs--20 years' experience.

Authors:  I M Nilsson; U Hedner; A Ahlberg; S A Larsson; S E Bergentz
Journal:  World J Surg       Date:  1977-01       Impact factor: 3.352

Review 2.  Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.

Authors:  Amy D Shapiro; Ulla Hedner
Journal:  Ther Adv Drug Saf       Date:  2011-10

Review 3.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.

Authors:  I M Nilsson; E Berntorp; O Zettervall
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.

Authors:  T Révész; J Mátyus; B Goldschmidt; V Harsanyi
Journal:  Arch Dis Child       Date:  1980-08       Impact factor: 3.791

6.  Management of Odontogenic Fascial Space Infection in Hemophilia Patients: A Proposed Protocol.

Authors:  Md Kalim Ansari; Ghulam Sarwar Hashmi; Syed Saeed Ahmed; Sajjad Abdur Rahman; Tabishur Rahman
Journal:  J Maxillofac Oral Surg       Date:  2018-05-09

7.  "Antihemophilic factor is not the only answer for all factor VIII deficiencies." Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity.

Authors:  K M Sudheesh; K S N Siva Bharani; H Y Kiran; Suresh Hanagavadi
Journal:  Indian J Dent       Date:  2016-09

8.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.